about
The use of FDG-PET in diffuse large B cell lymphoma (DLBCL): predicting outcome following first line therapyAsian-variant intravascular lymphoma in the African raceThe predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scaleOn the added value of baseline FDG-PET in malignant lymphoma.Medical applications and toxicities of gallium compounds.Fluorodeoxyglucose-PET/CT for diagnosis of intravascular large B-cell lymphoma.Surveillance CT scans are a source of anxiety and fear of recurrence in long-term lymphoma survivors.My treatment approach to patients with diffuse large B-cell lymphoma.Interim FDG-PET Scan in Hodgkin's Lymphoma: Hopes and CaveatsPrognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era.Prognostic Value and Clinical Impact of (18)FDG-PET in the Management of Children with Burkitt Lymphoma after Induction Chemotherapy.Pulmonary intravascular lymphoma diagnosed by 18-fluorodeoxyglucose positron emission tomography-guided transbronchial lung biopsy in a man with long-term survival: a case reportFluorine-18 fluorodeoxyglucose PET-CT for extranodal staging of non-Hodgkin and Hodgkin lymphoma.18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in the Management of Aggressive Non-Hodgkin's B-Cell LymphomaCan Positron Emission Tomography and Computed Tomography Be a Substitute for Bone Marrow Biopsy in Detection of Bone Marrow Involvement in Patients with Hodgkin's or Non-Hodgkin's Lymphoma?18F-fluorodeoxyglucose Positron Emission Tomography in Kaposi Sarcoma Herpesvirus-Associated Multicentric Castleman Disease: Correlation With Activity, Severity, Inflammatory and Virologic Parameters.Radiation exposure and mortality risk from CT and PET imaging of patients with malignant lymphoma.Clinical significance of standardized uptake value and maximum tumor diameter in patients with primary extranodal diffuse large B cell lymphoma.How to study optimal timing of PET/CT for monitoring of cancer treatmentPrognostic values of interim and post-therapy 18F-FDG PET/CT scanning in adult patients with Burkitt's lymphoma.Positron emission tomographic scans in lymphoma: convention and controversy.Maximum standard uptake value of 18F-fluorodeoxyglucose positron emission tomography is a prognostic factor for progression-free survival of newly diagnosed patients with diffuse large B cell lymphoma.Prediction of Central Nervous System Relapse of Diffuse Large B-Cell Lymphoma Using Pretherapeutic [18F]2-Fluoro-2-Deoxyglucose (FDG) Positron Emission Tomography/Computed Tomography.The role of fluorodeoxyglucose positron emission tomography-computerized tomography in resolving therapeutic dilemmas in pediatric Hodgkin lymphomaDiffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic MonitoringFluorine-18 fluorodeoxyglucose positron emission tomography imaging of T-lymphoblastic lymphoma patients.Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma.Multiple hypovascular tumors in kidney: a rare case report and differential diagnosis.Meta-analysis of the technical performance of an imaging procedure: guidelines and statistical methodology.Mucosa-associated lymphoid tissue lymphoma with unusual 18F-FDG hypermetabolism arising at the colorectal anastomosis.FDG-PET imaging in hematological malignanciesThe role of transplantation in diffuse large B-cell lymphoma: the impact of rituximab plus chemotherapy in first-line and relapsed settings.The challenges of integrating molecular imaging into the optimization of cancer therapy.Positron emission tomography findings in clinical mimics of lymphoma.Impact of FDG-PET/CT in the management of lymphoma.Molecular imaging for personalized cancer care.Value of 18FDG PET scan in staging of ocular adnexal lymphomas: a large single-center experience.Minimal residual disease detection in lymphoma and multiple myeloma: impact on therapeutic paradigms.Case of autoimmune hepatitis with markedly enlarged hepatoduodenal ligament lymph nodes.Clinical implications and prognostic role of minimal residual disease detection in follicular lymphoma
P2860
Q26863624-B87E4979-A1BE-42BD-807E-272C68444C45Q33400916-D9BE52A0-5D8D-45AE-B841-56CC38BAC1BEQ33696003-3A683CA1-59A3-4454-AB6D-B08FFE57BA63Q33749537-F3CFAB05-FCD7-4427-96FD-92DB141E7AF7Q33965885-7512C6DD-E69F-4041-AA25-22A4FF9E4E4AQ34030952-7C3EA7A6-4CC6-4F0A-A86E-3FEB4DBE4FF4Q34231093-28707E74-A4F5-4A6F-A044-7E67CE15EB73Q34251964-8596A11A-BE16-4713-81C4-A86822BF850AQ34475763-0E91F7BA-FFB8-4B4F-A707-39D03B036934Q34882773-B2C4BA0F-EE35-43EE-A379-DBC2898847F6Q34931319-90E27365-44DB-4596-8804-EA5F2BF317FDQ35153880-10F58FDE-35B5-49F4-8F00-2CE5054158C9Q35720831-F1D9D09F-8744-4865-A049-B659DE17C33CQ35855599-BD2F0581-3878-4B89-8AA0-BA559B177DEDQ36038881-338FD454-D321-4DAA-9F3E-B933C6451FBEQ36078761-702C2DCC-8FD2-47A4-9279-947D78C3E390Q36138213-BB12D002-558A-44C1-A0F5-5E134A066C67Q36297659-76504832-C687-4EEC-B75A-29F4D4EBEB1CQ36337232-2BE1B5D9-E96E-4C61-8078-8026B58590C8Q36344057-2801EC24-35B5-4A68-B5BE-EA85ED78DDCBQ36399538-BF4F5A1B-CA6A-413D-8733-43757B0A8481Q36524619-81F49731-4B3C-40A8-A2EA-B75D7D66B7BBQ37026232-F136FDE0-F357-43CD-9F6B-7AFDC2BEC873Q37058257-D162B939-71F7-4703-8155-CF8A4CCE7470Q37069297-56B56B8E-7DEC-4FF0-9683-300E5E647083Q37107545-3E1F1F20-22F4-42D8-B8DC-A387D6F887F0Q37326204-EB601F98-D9D2-4916-A3E9-0E00F504186EQ37400765-FC68069C-9D50-46BB-8687-B5D072560E21Q37580804-6BC11C7C-3EB6-471B-B672-CB8D227CC666Q37624527-8222EA97-5302-41FC-B113-C42CB267D00FQ37632114-7A592CEA-77CB-4E5C-A136-D5A7FDED1AEBQ37824456-27F0207C-817D-4A45-9BD4-64ED2E4ED69EQ37871875-B4DA7DF6-7384-4021-B248-35055FA7A551Q37896130-2A4B4039-C005-4DD0-9041-562366C8DF13Q37950857-8C2DDBBB-A35F-466C-A166-9290370C527EQ37999206-864EAED7-B559-48D9-8439-435AE0A4D5EFQ38015946-160D326A-F2DB-4E5F-B980-E02FA60FCA14Q38017138-98680DCE-58CF-44C4-BB71-F57F21D78C35Q38095933-FD6F3999-51E4-4CD6-8CD6-AD090A2251E7Q38111389-10A30375-1438-441E-BFC2-1DB86FE546E4
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
The role of FDG-PET scans in patients with lymphoma.
@en
type
label
The role of FDG-PET scans in patients with lymphoma.
@en
prefLabel
The role of FDG-PET scans in patients with lymphoma.
@en
P2093
P1433
P1476
The role of FDG-PET scans in patients with lymphoma.
@en
P2093
Bruce D Cheson
Malik E Juweid
Pamela Seam
P304
P356
10.1182/BLOOD-2007-06-097238
P407
P577
2007-08-20T00:00:00Z